Articles

Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results

Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem
Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem
Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem
Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem
Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem
Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem
Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem
Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem
Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem
Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem
Department of Hematology, Aviv Medical Center, Sackler faculty of medicine, Aviv University
Department of Hematology, Aviv Medical Center, Sackler faculty of medicine, Aviv University
Laboratory of Tumor Immunology and Immunotherapy, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan 52900-02, Israel
Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem
Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem
Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem
Haematologica Early view Oct 6, 2022 https://doi.org/10.3324/haematol.2022.281628